$2.76m R&D Tax Incentive Cash Rebate Received for FY24
Filed with ASX · · 1 page · English
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- Quarterly Activities/Appendix 4C Cash Flow Report - updated
- FDA Grants ODD & RPDD for Second Drug in Treatment of HIE
- Positive Results in Key IND Enabling Studies
- Appendix 4E & Annual Report to 30 June 2024
- ARG-007 Reduces Effects of TBI in Preclinical Study
Later from Argenica Therapeutics
- Phase 2 Stroke Clinical Trial Update
- Positive DSMB Safety Outcome & Phase 2 Trial Progress Update
- ARG-007 Shows Significant Neuroprotection in Main TBI Study
- Updated - Main TBI Injury Study Annoucement
- Last Patient Dosed in Phase 2 Stroke Trial
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics